Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Capital Expenditures (2016 - 2025)

Altimmune (ALT) has disclosed Capital Expenditures for 13 consecutive years, with -$4000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Capital Expenditures fell 121.05% to -$4000.0 in Q2 2023 year-over-year; TTM through Sep 2025 was -$4000.0, a N/A change, with the full-year FY2023 number at $47000.0, down 62.7% from a year prior.
  • Capital Expenditures was -$4000.0 for Q2 2023 at Altimmune, down from $51000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.7 million in Q2 2021 to a low of -$4000.0 in Q2 2023.
  • A 5-year average of $780949.0 and a median of $44500.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 5972700.0% in 2020, then tumbled 121.05% in 2023.
  • Altimmune's Capital Expenditures stood at $1.0 in 2019, then surged by 10362700.0% to $103628.0 in 2020, then skyrocketed by 41.85% to $147000.0 in 2021, then tumbled by 74.15% to $38000.0 in 2022, then plummeted by 110.53% to -$4000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALT's Capital Expenditures are -$4000.0 (Q2 2023), $51000.0 (Q1 2023), and $38000.0 (Q4 2022).